UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) will host a virtual Research & Development Day on June 22, 2021, from 8:30 to 11:30 a.m. ET, focusing on its expanding gene therapy pipeline for CNS and liver-directed disorders. The company will also participate in multiple upcoming virtual conferences including the Jefferies Virtual Healthcare Conference (June 1-4), European Hematology Association Virtual 2021 (June 7-13), and Goldman Sachs 42nd Annual Global Healthcare Conference (June 8-11). Notably, results from the pivotal Phase 3 HOPE-B trial will be presented during the EHA conference.

~ uniQure to host virtual Research & Development Day on June 22, 2021 ~

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

• Jefferies Virtual Healthcare Conference, June 1 - 4, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 2.
    
    
  • A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• European Hematology Association (EHA) Virtual 2021, June 7 - 13, 2021
  
  
  • uniQure will present two encore presentations respectively highlighting 26-week clinical data from the pivotal Phase 3 HOPE-B trial of the gene therapy etranacogene dezaparvovec in patients with severe to moderately severe hemophilia B.
    
    
    • An oral presentation entitled “26 Week Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua HFIX Variant; AMT-130) in Adults with Severe or Moderate-Severe Hemophilia B Treated in the Phase 3 HOPE-B Clinical Trial” will be available on June 11, 2021 at 9:00 a.m. ET.
      
      
    • A poster presentation entitled “Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec” will be available on June 11, 2021 at 9:00 a.m. ET
      
      
• Goldman Sachs 42^nd Annual Global Healthcare Conference, June 8 - 11, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, June 8.
    
    
  • Matt Kapusta will participate in a fireside chat the same day at 4:40 to 5:20 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• uniQure’s Virtual Research & Development Day, June 22, 2021
  
  
  • uniQure will host a virtual Research & Development Day on June 22, 2021 at 8:30 to 11:30 a.m. ET to highlight new investments in its expanding gene therapy pipeline focusing on CNS and rare, liver-directed disorders, as well as new advancements in platform technology and manufacturing. Additional details can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.  
    
    
• Raymond James Virtual Human Health Innovation Conference, June 21 - 23, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 23.
    
    
  • Ricardo Dolmetsch, president of research and development, will participate in a panel entitled “Therapeutic Targets for Huntington’s Disease: We (Still) Down with HTT?”, from 9:20 to 10:10 a.m. ET.
    
    
  • A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 9:10 to 9:35 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

 

FAQ

What is the date for uniQure's virtual Research & Development Day?

uniQure's virtual Research & Development Day is scheduled for June 22, 2021.

What key presentations will uniQure showcase at the EHA Virtual 2021 conference?

uniQure will present two encore presentations highlighting 26-week clinical data from the pivotal Phase 3 HOPE-B trial of etranacogene dezaparvovec for hemophilia B.

When will the fireside chat with Matt Kapusta take place?

The fireside chat with Matt Kapusta is set for June 2, 2021, from 8:30 to 8:55 a.m. ET.

What is the focus of uniQure's gene therapy pipeline?

uniQure's gene therapy pipeline focuses on CNS disorders and rare, liver-directed diseases.

Where can I access the live webcasts for uniQure's presentations?

Live webcasts for uniQure's presentations can be accessed through the Investors & Newsroom section of the uniQure website.